X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs LUPIN LTD - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA LUPIN LTD AUROBINDO PHARMA/
LUPIN LTD
 
P/E (TTM) x 14.6 19.9 73.5% View Chart
P/BV x 3.8 2.7 139.3% View Chart
Dividend Yield % 0.4 0.9 44.7%  

Financials

 AUROBINDO PHARMA   LUPIN LTD
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
LUPIN LTD
Mar-17
AUROBINDO PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs8951,750 51.1%   
Low Rs6221,384 45.0%   
Sales per share (Unadj.) Rs254.6387.4 65.7%  
Earnings per share (Unadj.) Rs39.356.6 69.4%  
Cash flow per share (Unadj.) Rs46.676.8 60.6%  
Dividends per share (Unadj.) Rs2.507.50 33.3%  
Dividend yield (eoy) %0.30.5 68.9%  
Book value per share (Unadj.) Rs160.0298.9 53.5%  
Shares outstanding (eoy) m585.88451.58 129.7%   
Bonus/Rights/Conversions ESOPESOPS-  
Price / Sales ratio x3.04.0 73.7%   
Avg P/E ratio x19.327.7 69.8%  
P/CF ratio (eoy) x16.320.4 79.9%  
Price / Book Value ratio x4.75.2 90.5%  
Dividend payout %6.413.2 48.1%   
Avg Mkt Cap Rs m444,390707,513 62.8%   
No. of employees `00014.016.8 83.3%   
Total wages/salary Rs m17,67828,495 62.0%   
Avg. sales/employee Rs Th10,667.810,418.3 102.4%   
Avg. wages/employee Rs Th1,264.31,697.0 74.5%   
Avg. net profit/employee Rs Th1,645.81,523.0 108.1%   
INCOME DATA
Net Sales Rs m149,157174,943 85.3%  
Other income Rs m1,1591,065 108.8%   
Total revenues Rs m150,316176,008 85.4%   
Gross profit Rs m34,34344,931 76.4%  
Depreciation Rs m4,2769,122 46.9%   
Interest Rs m6671,525 43.7%   
Profit before tax Rs m30,55835,349 86.4%   
Minority Interest Rs m50-72 -70.0%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,5979,785 77.6%   
Profit after tax Rs m23,01225,575 90.0%  
Gross profit margin %23.025.7 89.6%  
Effective tax rate %24.927.7 89.8%   
Net profit margin %15.414.6 105.5%  
BALANCE SHEET DATA
Current assets Rs m92,062119,542 77.0%   
Current liabilities Rs m66,22361,206 108.2%   
Net working cap to sales %17.333.3 52.0%  
Current ratio x1.42.0 71.2%  
Inventory Days Days10676 139.5%  
Debtors Days Days6890 75.3%  
Net fixed assets Rs m62,919131,660 47.8%   
Share capital Rs m586903 64.9%   
"Free" reserves Rs m93,133134,073 69.5%   
Net worth Rs m93,719134,976 69.4%   
Long term debt Rs m1,81456,478 3.2%   
Total assets Rs m162,494266,073 61.1%  
Interest coverage x46.824.2 193.6%   
Debt to equity ratio x00.4 4.6%  
Sales to assets ratio x0.90.7 139.6%   
Return on assets %14.610.2 143.1%  
Return on equity %24.618.9 129.6%  
Return on capital %32.719.3 169.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m75,83881,885 92.6%   
Fx outflow Rs m30,22421,506 140.5%   
Net fx Rs m45,61360,378 75.5%   
CASH FLOW
From Operations Rs m32,78641,148 79.7%  
From Investments Rs m-17,870-25,287 70.7%  
From Financial Activity Rs m-19,1534,332 -442.1%  
Net Cashflow Rs m-4,23920,193 -21.0%  

Share Holding

Indian Promoters % 54.1 46.6 116.1%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 8.0 11.3 70.4%  
FIIs % 27.7 31.9 86.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 10.1 101.0%  
Shareholders   69,601 98,259 70.8%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS